- Home
- WEC vs ONC Comparison
WEC vs ONC Comparison
Compare WEC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEC
- ONC
- Stock Information
- Founded
- WEC 1896
- ONC 2010
- Country
- WEC United States
- ONC Switzerland
- Employees
- WEC N/A
- ONC N/A
- Industry
- WEC Power Generation
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- WEC Utilities
- ONC Health Care
- Exchange
- WEC Nasdaq
- ONC Nasdaq
- Market Cap
- WEC 33.8B
- ONC 31.5B
- IPO Year
- WEC N/A
- ONC N/A
- Fundamental
- Price
- WEC $110.25
- ONC $299.01
- Analyst Decision
- WEC Hold
- ONC Strong Buy
- Analyst Count
- WEC 10
- ONC 9
- Target Price
- WEC $104.60
- ONC $332.44
- AVG Volume (30 Days)
- WEC 1.9M
- ONC 411.4K
- Earning Date
- WEC 07-30-2025
- ONC 08-06-2025
- Dividend Yield
- WEC 3.24%
- ONC N/A
- EPS Growth
- WEC 20.31
- ONC N/A
- EPS
- WEC 5.22
- ONC N/A
- Revenue
- WEC $9,306,700,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- WEC $9.35
- ONC $865.19
- Revenue Next Year
- WEC $5.28
- ONC $21.12
- P/E Ratio
- WEC $21.14
- ONC N/A
- Revenue Growth
- WEC 7.88
- ONC 51.16
- 52 Week Low
- WEC $86.09
- ONC $155.75
- 52 Week High
- WEC $111.07
- ONC $308.87
- Technical
- Relative Strength Index (RSI)
- WEC 63.43
- ONC N/A
- Support Level
- WEC $107.92
- ONC N/A
- Resistance Level
- WEC $110.08
- ONC N/A
- Average True Range (ATR)
- WEC 1.63
- ONC 0.00
- MACD
- WEC 0.21
- ONC 0.00
- Stochastic Oscillator
- WEC 88.13
- ONC 0.00
About WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 32% gas distribution, 10% electric transmission, 7% unregulated renewable energy and 2% LNG distribution and generation.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.